• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    LeMaitre Vascular Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    6/3/24 4:21:10 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care
    Get the next $LMAT alert in real time by email
    lmat20240603_8k.htm
    false 0001158895 0001158895 2024-06-03 2024-06-03
     

     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549
     

     
    FORM8-K
    CURRENT REPORT
     
    PURSUANT TO SECTION 13 OR 15(0) OF THE SECURITIES EXCHANGE ACT OF 1934
     
    Date of report (Date of earliest event reported): June 3, 2024
     

     
    LeMaitre Vascular, Inc.
    (Exact Name of Registrant as Specified in Its Charter)
     

     
    Delaware
     
    (State or Other Jurisdiction of Incorporation)
     
    001-33092 04-2825458
    (Commission File Number) (IRS Employer Identification No.)
       
    63 Second Avenue 01803
    Burlington, Massachusetts (Zip Code)
    (Address of Principal Executive Offices)  
     
    (781) 221-2266
    (Registrant's Telephone Number, Including Area Code)
     

     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Exchange Act:
     
    Securities registered pursuant to Section 12(b) of the Exchange Act:
     
    Title of each class
    Trading Symbol(s)
    Name of each exchange on which registered
    Common
    LMAT
    The Nasdaq Global Market
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
     
    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. D
     
     

     
     
    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
     
    (b)         The disclosure in Item 5.07 regarding the resignation of Mr. Jasinski as a director of LeMaitre Vascular, Inc. (the “Company”), contingent upon acceptance by the Board of Directors, and the subsequent rejection by the Board of Directors of this resignation is incorporated herein by reference.
     
    (e)         As described in Item 5.07 below, on June 3, 2024, the shareholders of the Company approved an amendment and restatement of the LeMaitre Vascular, Inc. Fourth Amended and Restated 2006 Stock Option and Incentive Plan (the “Amended Plan”), which authorizes 1,000,000 new shares for issuance under the Amended Plan and makes certain other changes, including limiting when shares covered by awards are restored to the status of being available for grant, providing limits on the vesting of awards, and extending the term of the Amended Plan until June 3, 2034. A description of the material terms and conditions of the Amended Plan is provided in Proposal 3 of the Company’s definitive proxy statement for the 2024 annual meeting of shareholders, which was filed with the Securities and Exchange Commission on April 16, 2024, and is incorporated herein by reference.
     
    The foregoing description of the Amended Plan is qualified in its entirety by reference to a full and complete copy of the Amended Plan, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
     
    Item 5.07. Submission of Matters to a Vote of Security Holders.
     
    (a)         On June 3, 2024, the Company held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). A total of 22,445,999 shares of the Company's common stock were entitled to vote as of April 5, 2024, the record date for the Annual Meeting, of which 20,754,390.159778 shares were present in person or represented by proxy at the Annual Meeting.
     
    (b)         Matters voted upon by the stockholders at the Annual Meeting were: (i) the election of three Class III directors nominated by the Board of Directors for three-year terms; (ii) an advisory vote on the compensation of the Company's named executive officers; (iii) approval of the Fourth Amended and Restated 2006 Stock Option and Incentive Plan; and (iv) the ratification of the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for 2024.
     
    Set forth below is information concerning each matter submitted to a vote at the Annual Meeting.
     
    Proposal No.1 – Election of Directors
     
    By a majority of votes cast, the stockholders elected the following three nominees as Class III directors for a term of three years expiring upon the 2027 Annual Meeting of Stockholders or until their successor has been duly elected and qualified. John J. O’Connor received a vote of 18,829,637.159778 shares for, 915,672 shares withheld and 1,009,081 broker non-votes. Joseph P. Pellegrino, Jr. received a vote of 16,654,880.159778 shares for, 2,933,313 shares withheld and 1,166,197 broker non-votes. Lawrence J. Jasinski received a vote of 8,277,096.159778 shares for, 11,308,332 shares withheld and 1,168,962 broker non-votes.
     
    Having received fewer votes “for” his election than votes “against” his election, on June 3, 2024, Mr. Jasinski tendered his resignation, subject to Board approval, in accordance with the Company’s Corporate Governance Guidelines. The Board met on June 3, 2024, and rejected Mr. Jasinski’s resignation after considering the recommendation of the Nominating and Corporate Governance Committee and the contributions of Mr. Jasinski to the Board of Directors and the Company.
     
    Proposal No. 2 – Advisory Vote on Executive Compensation
     
    By a majority of votes cast, the stockholders approved, on an advisory basis, the Company's executive compensation by a vote of 19,118,371.159778 shares for and 624,991 shares against, 10,798 shares abstaining, and 1,000,230 broker non-votes.
     
    Proposal No.3 – Approval of the Fourth Amended and Restated 2006 Stock Option and Incentive Plan
     
    By a majority of votes cast, the stockholders approved the Fourth Amended and Restated 2006 Stock Option and Incentive Plan with a vote of 19,332,353.159778 shares for and 411,532 shares against, 10,275 shares abstaining, and 1,000,230 broker non-votes.
     
    Proposal No.4 – Ratification of the Selection of Independent Registered Public Accounting Firm
     
    By a majority of votes cast, the stockholders ratified the selection of Grant Thornton L LP as the Company's independent registered public accounting firm for the year ending December 31, 2024, with a vote of 20,642,552.159778 shares for, 93,844 shares against, and 17,994 shares abstaining.
     
    Item 9.01 Financial Statements and Exhibits.
     
    (d) Exhibits
    Exhibit Number
     
    Description
    10.1
     
    LeMaitre Vascular, Inc. Fourth Amended and Restated 2006 Stock Option and Incentive Plan
    104
     
    Cover Page Interactive Data File (embedded within the Inline XBRL document)
     
     

     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
      LEMAITRE VASCULAR, INC.  
    Dated: June 3, 2024 By: /s/ Joseph P. Pellegrino, Jr.  
        Nme: Joseph P. Pellegrino, Jr.  
        Title: Chief Financial Officer and Secretary  
     
     
    Get the next $LMAT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LMAT

    DatePrice TargetRatingAnalyst
    8/6/2025$95.00Mkt Perform → Outperform
    Barrington Research
    2/28/2025Outperform → Perform
    Oppenheimer
    2/28/2025Outperform → Mkt Perform
    Barrington Research
    2/13/2025$95.00Equal Weight
    Wells Fargo
    10/15/2024$96.00Neutral
    Cantor Fitzgerald
    8/2/2024$85.00 → $105.00Buy
    Lake Street
    5/31/2024$100.00Buy
    ROTH MKM
    4/26/2024$59.00 → $75.00Hold → Buy
    Stifel
    More analyst ratings

    $LMAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lemaitre Vascular upgraded by Barrington Research with a new price target

    Barrington Research upgraded Lemaitre Vascular from Mkt Perform to Outperform and set a new price target of $95.00

    8/6/25 7:37:02 AM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    Lemaitre Vascular downgraded by Oppenheimer

    Oppenheimer downgraded Lemaitre Vascular from Outperform to Perform

    2/28/25 8:28:09 AM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    Lemaitre Vascular downgraded by Barrington Research

    Barrington Research downgraded Lemaitre Vascular from Outperform to Mkt Perform

    2/28/25 7:39:54 AM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    $LMAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $LMAT
    SEC Filings

    View All

    SEC Form 4 filed by Shadan Martha

    4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)

    3/30/26 6:10:02 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Ross Bridget A

    4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)

    3/30/26 6:03:09 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by O'Connor John James

    4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)

    3/30/26 6:02:41 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by LeMaitre Vascular Inc.

    SCHEDULE 13G/A - LEMAITRE VASCULAR INC (0001158895) (Subject)

    3/27/26 10:21:11 AM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by LeMaitre Vascular Inc.

    10-K - LEMAITRE VASCULAR INC (0001158895) (Filer)

    2/26/26 7:01:03 AM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    LeMaitre Vascular Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - LEMAITRE VASCULAR INC (0001158895) (Filer)

    2/25/26 4:54:33 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    $LMAT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LeMaitre to Participate at Upcoming Investor Conferences in March

    BURLINGTON, Mass., Feb. 27, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that management will be participating in five upcoming investor conferences in March. Leerink Partners Global Healthcare ConferenceTuesday, March 10, 2026W South Beach, MiamiManagement will present at 1:00 PM EDT Citizens Life Sciences ConferenceWednesday, March 11, 2026Eden Roc Miami Beach, MiamiManagement will present at 1:40 PM EDT Barclays Annual Global Healthcare ConferenceThursday, March 12, 2026Management will be available for 1x1 meetings KeyBanc Capital Markets Healthcare ForumTuesday, March 17, 2026VirtualManagement will present at 3:45 PM EDT 38th Annual ROTH Conferenc

    2/27/26 2:50:37 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    LeMaitre Q4 2025 Financial Results

    BURLINGTON, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of vascular devices, implants, and services, today reported Q4 2025 results, announced a quarterly dividend of $0.25/share (+25%), and provided guidance. Q4 2025: Sales $64.5mm, +16% (+15% organic) vs. Q4 2024Gross margin 71.7% (+240 bps)Op. income $18.8mm (+47%)Op. margin 29%Diluted EPS $0.68 (+39%)Cash up $16.1mm sequentially to $359.1mm Grafts (+27%), valvulotomes (+20%), and carotid shunts (+18%) drove Q4 sales growth. EMEA sales increased 29%, APAC 20%, and the Americas 10%. Gross margin of 71.7% (+240 bps) increased due to higher average selling prices and manufacturing efficien

    2/25/26 4:05:00 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    LeMaitre Will Announce Fourth Quarter 2025 Earnings Results February 25, 2026

    BURLINGTON, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its fourth quarter 2025 financial results on Wednesday, February 25, 2026, after the market close. The company has scheduled a conference call for 5:00 PM EST the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants, and services for t

    2/11/26 9:47:47 AM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    $LMAT
    Financials

    Live finance-specific insights

    View All

    LeMaitre Q4 2025 Financial Results

    BURLINGTON, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of vascular devices, implants, and services, today reported Q4 2025 results, announced a quarterly dividend of $0.25/share (+25%), and provided guidance. Q4 2025: Sales $64.5mm, +16% (+15% organic) vs. Q4 2024Gross margin 71.7% (+240 bps)Op. income $18.8mm (+47%)Op. margin 29%Diluted EPS $0.68 (+39%)Cash up $16.1mm sequentially to $359.1mm Grafts (+27%), valvulotomes (+20%), and carotid shunts (+18%) drove Q4 sales growth. EMEA sales increased 29%, APAC 20%, and the Americas 10%. Gross margin of 71.7% (+240 bps) increased due to higher average selling prices and manufacturing efficien

    2/25/26 4:05:00 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    LeMaitre Will Announce Fourth Quarter 2025 Earnings Results February 25, 2026

    BURLINGTON, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its fourth quarter 2025 financial results on Wednesday, February 25, 2026, after the market close. The company has scheduled a conference call for 5:00 PM EST the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants, and services for t

    2/11/26 9:47:47 AM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    LeMaitre Q3 2025 Financial Results

    BURLINGTON, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of vascular devices, implants, and services, today reported Q3 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance. Q3 2025 results include a non-recurring benefit from the Employee Retention Tax Credit. Non-GAAP adjusted figures exclude this benefit. A reconciliation of GAAP to non-GAAP results is included. Q3 2025: Sales $61.0mm, +11% (+12% organic)Gross margin 75.3% (+750 bps), adjusted 70.8% (+300 bps)Op. income $20.3mm (+54%), adjusted $16.9mm (+29%)Op. margin 33%, adjusted 28%Diluted EPS $0.75 (+54%), adjusted $0.62 (+27%)Cash up $23.6mm sequentiall

    11/6/25 4:05:00 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    $LMAT
    Leadership Updates

    Live Leadership Updates

    View All

    Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

    MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its Board of Directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director. "On behalf of the management team and Board, I am delighted to welcome David and Gregory to the Company" commented John Seaberg, Chairman o

    6/9/25 10:52:06 PM ET
    $AVR
    $LMAT
    Industrial Specialties
    Health Care
    Medical/Dental Instruments

    Precision Optics Appoints Joseph P. Pellegrino, Jr. to Board of Directors

    GARDNER, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Joseph P. "JJ" Pellegrino, Jr. to its Board of Directors. Mr. Pellegrino, who will also serve as Chairman of the Board's Audit Committee, brings decades of operational and financial experience as well as an extensive knowledge of the medical device industry to the board. Mr. Pellegrino most recently served as Chief Financial Officer of LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of devices, implants and services for the treatm

    3/20/25 9:00:00 AM ET
    $LMAT
    $POCI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    Former Johnson & Johnson Executive Joins Advisory Board at Maitri Health Technologies

    Bridget Ross brings extensive experience in MedTech development and services;Joins advisory board of healthcare, logistics, capital markets and innovation leaders VANCOUVER, BC, March 23, 2021 /PRNewswire/ - Maitri Health Technologies Corp. ("Maitri") (CSE: MTEC) (FRA: D84), a global platform for healthcare supply security, today announced the appointment of Bridget Ross to its Advisory Board. Ms. Ross is currently CEO of ChroniSense Medical, Ltd., an Israel-based MedTech company and maker of wearable, medical-grade disease management devices. Ms. Ross serves as a Board Director for LeMaitre Vascular Inc. (NASDAQ: LMAT) and as a mentor for early stage MedTech companies through MassMEDIC and

    3/23/21 8:00:00 AM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    $LMAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by LeMaitre Vascular Inc.

    SC 13G - LEMAITRE VASCULAR INC (0001158895) (Subject)

    10/22/24 3:49:21 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by LeMaitre Vascular Inc. (Amendment)

    SC 13G/A - LEMAITRE VASCULAR INC (0001158895) (Subject)

    2/13/24 5:08:02 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by LeMaitre Vascular Inc. (Amendment)

    SC 13G/A - LEMAITRE VASCULAR INC (0001158895) (Subject)

    2/12/24 3:02:21 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care